Nine prominent drug candidates are awaiting an FDA approval decision in the next few months. With the help of Biomedtracker's Early 2022 Outlook Report, we take a look at the potential launches likely to shake up the market from HIV to wet AMD.

Chaos wrought by the ongoing coronavirus pandemic. A heavy workload and continuing resource constraints at the European Medicines Agency. Nonetheless, a record number of novel drugs and vaccines were cleared for marketing in the EU last year.

The Pink Sheet's list of EU centralized approvals of new active substances has been updated to include five new products, including Roche’s Enspryng for neuromyelitis optica spectrum disorder.

Gedeon Richter aims to continue the global roll-out of its teriparatide biosimilar, having enjoyed continued solid growth for the Forsteo rival during the first quarter.